Cargando…

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials

RATIONALE: Exacerbations of chronic obstructive pulmonary disease (COPD) are an important endpoint in multinational clinical treatment trials, but the observed event rate is often lower than anticipated and appears to vary between countries. OBJECTIVES: We investigated whether systematic differences...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calverley, Peter M. A., Martinez, Fernando J., Vestbo, Jørgen, Jenkins, Christine R., Wise, Robert, Lipson, David A., Cowans, Nicholas J., Yates, Julie, Crim, Courtney, Celli, Bartolome R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954323/ https://www.ncbi.nlm.nih.gov/pubmed/35363593 http://dx.doi.org/10.1164/rccm.202111-2630OC

Ejemplares similares

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review
por: Celli, Bartolome R., et al.
Publicado: (2021)

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018)

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
por: Adamson, Philip D., et al.
Publicado: (2018)

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
por: Jenkins, Christine R, et al.
Publicado: (2009)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
por: Jones, Paul W, et al.
Publicado: (2011)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial
por: Wise, Robert A, et al.
Publicado: (2020)

Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD
por: Fawzy, Ashraf, et al.
Publicado: (2019)

Reply to Fisk and Wilkinson: Aortic Pulse Wave Velocity Predicts All-Cause Mortality in Chronic Obstructive Pulmonary Disease
por: Crim, Courtney, et al.
Publicado: (2020)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

The severity of airways obstruction as a determinant of treatment response in COPD
por: Calverley, Peter MA, et al.
Publicado: (2006)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort
por: Celli, Bartolome, et al.
Publicado: (2021)

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
por: Agustí, Alvar, et al.
Publicado: (2012)

A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease
por: Hardin, Megan, et al.
Publicado: (2015)

Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD
por: Vestbo, Jørgen, et al.
Publicado: (2022)

Markers of exacerbation severity in chronic obstructive pulmonary disease
por: Franciosi, Luigi G, et al.
Publicado: (2006)

Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
por: Jenkins, Christine R., et al.
Publicado: (2015)

Prevention of COPD exacerbations: medications and other controversies
por: Vestbo, Jørgen, et al.
Publicado: (2015)

Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
por: Papadopoulou, Efthymia, et al.
Publicado: (2023)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Characterisation of COPD heterogeneity in the ECLIPSE cohort
por: Agusti, Alvar, et al.
Publicado: (2010)

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
por: Scott, David A, et al.
Publicado: (2015)

A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
por: Mathioudakis, Alexander G., et al.
Publicado: (2019)

Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
por: Mathioudakis, Alexander G, et al.
Publicado: (2020)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
por: Horne, Benjamin D, et al.
Publicado: (2021)

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(®) trial
por: Wise, Robert A, et al.
Publicado: (2018)

Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials
por: Mathioudakis, Alexander G., et al.
Publicado: (2019)

25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease
por: Quint, Jennifer K, et al.
Publicado: (2012)

Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
por: Vestbo, Jørgen
Publicado: (2020)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

Chronic obstructive pulmonary disease exacerbation frequency and severity
por: Stafyla, Eirini, et al.
Publicado: (2013)

Predictors of exacerbation frequency in chronic obstructive pulmonary disease
por: Yang, Hui, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hndf57j08nv62vg7v204go5t6n